logo

For the Inventor, By the Inventor

Rueil Malmaison, France

Eric Nicolai

USPTO Granted Patents = 18 

Average Co-Inventor Count = 3.3

ph-index = 8

Forward Citations = 145(Granted Patents)


Location History:

  • Caen, FR (1991 - 1994)
  • Rueil Malmaison, FR (1997 - 2007)

Company Filing History:

goldMedal7 out of 22 
 
Laboratoires Upsa
 patents
silverMedal5 out of 3,684 
 
Bristol-myers Squibb Compnay
 patents
bronzeMedal4 out of 5 
 
Cerep Sa
 patents
4. 3 out of 8 
 
Laboratories Upsa
 patents
5. 1 out of 36 
 
Bristol-myers Squibb
 patents
6. 1 out of 1 
 
Cerep
 patent
7. 1 out of 5,072 
 
Centre National De La Recherche Scientifique
 patents
8. 1 out of 1,743 
 
Institut National De La Sante Et De La Recherche Medicale
 patents
9. 1 out of 832,718 
Other
 patents
where one patent can have more than one assignee

Years Active: 1991-2007

Loading Chart...
18 patents (USPTO):Explore Patents
1. 7238693 - Aryl carbamate derivatives, preparation and use thereof (2007-07-03),
2. 7199125 - Spiro-cyclic compounds useful as anti-inflammatory agents (2007-04-03),
3. 7078420 - Spiro-hydantoin compounds useful as anti-inflammatory agents (2006-07-18),
4. 6977267 - Spiro-hydantoin compounds useful as anti-inflammatory agents (2005-12-20),
5. 6974815 - Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents (2005-12-13),
6. 6710064 - Hydantoin compounds useful as anti-inflammatory agents (2004-03-23),
7. 6673825 - Urazole compounds useful as anti-inflammatory agents (2004-01-06),
8. 6180651 - Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics (2001-01-30),
9. 6004994 - Heterocyclic diarylmethylene derivatives, methods of preparing them and (1999-12-21),
10. 5972950 - 1,2-diarylmethylene derivatives, their methods of preparation and their (1999-10-26),
11. 5840753 - 1,2 diarylmethylene derivatives, their methods of preparation and their (1998-11-24),
12. 5807873 - Diarylmethylidenefuran derivatives and their uses in therapeutics (1998-09-15),
13. 5686460 - Carbocyclic diarylmethylene derivatives, processes for their preparation (1997-11-11),
14. 5358950 - Triazolopyrimidine derivatives which are angiotensin II receptor (1994-10-25),
15. 5217973 - Triazolopyrimidine derivatives which are angiotensin II receptor (1993-06-08),

Title: Eric Nicolai: Innovator in Pharmaceutical Compounds

Introduction

Eric Nicolai is a prominent inventor based in Rueil Malmaison, France. He has made significant contributions to the field of pharmaceuticals, holding a total of 18 patents. His work primarily focuses on novel compounds that have therapeutic applications, particularly in human and animal health.

Latest Patents

Among his latest patents, Nicolai has developed aryl carbamate derivatives, which are novel compounds with potential therapeutic uses. These compounds are particularly relevant as 5-HT serotoninergic receptor ligands, which can be utilized in the treatment of disorders involving 5-HT receptors. Additionally, he has patented spiro-cyclic compounds that serve as anti-inflammatory agents, aimed at treating inflammatory and immune diseases. These compounds are characterized by specific structural formulas that enhance their efficacy in medical applications.

Career Highlights

Throughout his career, Nicolai has worked with notable companies such as Laboratoires Upsa and Bristol-Myers Squibb Company. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovation and development.

Collaborations

Nicolai has collaborated with esteemed colleagues, including Jean-Marie C. Teulon and Michele Launay. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Eric Nicolai's innovative work in the field of pharmaceuticals has led to the creation of valuable compounds that hold promise for therapeutic applications. His contributions continue to impact the health sector positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…